A new CHO (Chinese hamster ovary)-derived cell line expressing anti-TNFα monoclonal antibody with biosimilar potential

[1]  Patent expiry dates for biologicals : 2017 update , 2018 .

[2]  Li Zhuang,et al.  Sequential screening by ClonePix FL and intracellular staining facilitate isolation of high producer cell lines for monoclonal antibody manufacturing. , 2017, Journal of immunological methods.

[3]  B. Wettermark,et al.  Trends in medicines procurement by the Brazilian federal government from 2006 to 2013 , 2017, PloS one.

[4]  D. Furst,et al.  Biosimilars and the extrapolation of indications for inflammatory conditions , 2017, Biologics : targets & therapy.

[5]  D. Martens,et al.  Selection of chemically defined media for CHO cell fed-batch culture processes , 2016, Cytotechnology.

[6]  O. Okamoto,et al.  Genetic analyses of Per.C6 cell clones producing a therapeutic monoclonal antibody regarding productivity and long-term stability , 2016, Applied Microbiology and Biotechnology.

[7]  P. Norman.  Humira: the impending patent battles over adalimumab biosimilars. , 2016, Pharmaceutical patent analyst.

[8]  K. de Vlam,et al.  Treatment adherence, efficacy, and safety of etanercept in patients with active psoriatic arthritis and peripheral involvement in Belgium for 66 months (PROVE study). , 2015, Clinical and experimental rheumatology.

[9]  P. Rahman,et al.  Randomized Controlled Trial of Adalimumab in Patients With Nonpsoriatic Peripheral Spondyloarthritis , 2015, Arthritis & rheumatology.

[10]  L. R. Tsuruta,et al.  Biosimilars advancements: Moving on to the future , 2015, Biotechnology progress.

[11]  D. Ecker,et al.  The therapeutic monoclonal antibody market , 2015, mAbs.

[12]  Jagdeep Nanchahal,et al.  Anti-TNF therapy: past, present and future. , 2015, International immunology.

[13]  Raveendhara R. Bannuru,et al.  American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis , 2015 .

[14]  E. Wennerberg,et al.  Dysregulated Fc receptor function in active rheumatoid arthritis. , 2014, Immunology letters.

[15]  L. Scott.  Etanercept: A Review of Its Use in Autoimmune Inflammatory Diseases , 2014, Drugs.

[16]  P. Durez,et al.  Ten-year Followup of Infliximab Therapy in Rheumatoid Arthritis Patients with Severe, Longstanding Refractory Disease: A Cohort Study , 2014, The Journal of Rheumatology.

[17]  Benjamin S. Hughes,et al.  High-throughput ClonePix FL analysis of mAb-expressing clones using the UCOE expression system. , 2014, New biotechnology.

[18]  X. Mariette,et al.  Safety and effectiveness of adalimumab in patients with rheumatoid arthritis over 5 years of therapy in a phase 3b and subsequent postmarketing observational study , 2014, Arthritis Research & Therapy.

[19]  Jianxin Ye,et al.  Generation of cell lines for monoclonal antibody production. , 2014, Methods in molecular biology.

[20]  Suba Dharshanan,et al.  Screening and subcloning of high producer transfectomas using semisolid media and automated colony picker. , 2014, Methods in molecular biology.

[21]  M. C. Tuma,et al.  Strategies for clone detection, selection and isolation in Per.C6 cells - case for Rebmab100 , 2013, BMC Proceedings.

[22]  Ya-jun Guo,et al.  Comparison of the inhibition mechanisms of adalimumab and infliximab in treating tumor necrosis factor alpha-associated diseases from a molecular view , 2013 .

[23]  Ya-jun Guo,et al.  Comparison of the Inhibition Mechanisms of Adalimumab and Infliximab in Treating Tumor Necrosis Factor α-Associated Diseases from a Molecular View* , 2013, The Journal of Biological Chemistry.

[24]  M. Lindenmeyer,et al.  Distinct Contributions of TNF Receptor 1 and 2 to TNF-Induced Glomerular Inflammation in Mice , 2013, PloS one.

[25]  W. Sandborn,et al.  52-Week Efficacy of Adalimumab in Patients with Moderately to Severely Active Ulcerative Colitis Who Failed Corticosteroids and/or Immunosuppressants , 2013, Inflammatory bowel diseases.

[26]  A. Bourgoin,et al.  White paper: an outlook on U.S. biosimilar competition. , 2013, Drugs of today.

[27]  D. Bernhard,et al.  Inhibition of cell surface expression of endothelial adhesion molecules by ursolic acid prevents intimal hyperplasia of venous bypass grafts in rats. , 2012, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[28]  R. Hetzer,et al.  Cryopreservation of human vascular umbilical cord cells under good manufacturing practice conditions for future cell banks , 2012, Journal of Translational Medicine.

[29]  E. Sasso,et al.  Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEAL. , 2012, Journal of the American Academy of Dermatology.

[30]  Lucila Stange Rezende-Fronza,et al.  Brazilian Society of Rheumatology Consensus for the treatment of rheumatoid arthritis , 2012 .

[31]  H. Chong,et al.  Rapid automated selection of mammalian cell line secreting high level of humanized monoclonal antibody using Clone Pix FL system and the correlation between exterior median intensity and antibody productivity , 2011 .

[32]  M. Kosmač,et al.  Exploring the Binding Sites of Anti-Infliximab Antibodies in Pediatric Patients With Rheumatic Diseases Treated With Infliximab , 2011, Pediatric Research.

[33]  F. Acurcio,et al.  [Expenses of the Brazilian Ministry of Health for high-cost drugs: a demographic and clinical analysis]. , 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[34]  T. Brunner,et al.  TNF suppresses acute intestinal inflammation by inducing local glucocorticoid synthesis , 2010, The Journal of experimental medicine.

[35]  M. Brigido,et al.  Comparison of Humanized IgG and FvFc Anti-CD3 Monoclonal Antibodies Expressed in CHO Cells , 2010, Molecular biotechnology.

[36]  P. Bruhns,et al.  Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. , 2009, Blood.

[37]  M. Croft.  The role of TNF superfamily members in T-cell function and diseases , 2009, Nature Reviews Immunology.

[38]  Gil Y. Melmed,et al.  Certolizumab pegol , 2022, Nature Reviews Drug Discovery.

[39]  J. Malva,et al.  Tumor Necrosis Factor‐α Modulates Survival, Proliferation, and Neuronal Differentiation in Neonatal Subventricular Zone Cell Cultures , 2008, Stem cells.

[40]  Alexei Degterev,et al.  Identification of RIP1 kinase as a specific cellular target of necrostatins. , 2008, Nature chemical biology.

[41]  A. C. Zanini,et al.  Análise de custo do tratamento medicamentoso da artrite reumatóide , 2008 .

[42]  J. Bradley,et al.  TNF‐mediated inflammatory disease , 2008, The Journal of pathology.

[43]  M. Siemionow,et al.  Tumor necrosis factor alpha (TNF-alpha) receptor-II is required for TNF-alpha-induced leukocyte-endothelial interaction in vivo. , 2007, Blood.

[44]  K. Pfeffer,et al.  The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games , 2005, Immunology.

[45]  L. V. D. van de Putte,et al.  A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis. , 2002, The Journal of rheumatology.

[46]  R. Rau.  Adalimumab (a fully human anti-tumour necrosis factor α monoclonal antibody) in the treatment of active rheumatoid arthritis: the initial results of five trials , 2002, Annals of the rheumatic diseases.

[47]  J. Tschopp,et al.  The molecular architecture of the TNF superfamily. , 2002, Trends in biochemical sciences.

[48]  B. Aggarwal,et al.  Curcumin downregulates cell survival mechanisms in human prostate cancer cell lines , 2001, Oncogene.

[49]  S. Verbeek,et al.  Role of activatory Fc gamma RI and Fc gamma RIII and inhibitory Fc gamma RII in inflammation and cartilage destruction during experimental antigen-induced arthritis. , 2001, The American journal of pathology.

[50]  M. Karin,et al.  The alpha and beta subunits of IkappaB kinase (IKK) mediate TRAF2-dependent IKK recruitment to tumor necrosis factor (TNF) receptor 1 in response to TNF. , 2001, Molecular and cellular biology.

[51]  J. Kempeni.  Preliminary results of early clinical trials with the fully human anti-TNFα monoclonal antibody D2E7 , 1999, Annals of the rheumatic diseases.

[52]  A. Kornbluth.  Infliximab approved for use in Crohn's disease: a report on the FDA GI Advisory Committee conference. , 1998, Inflammatory bowel diseases.

[53]  C. Haslett,et al.  Regulation of neutrophil apoptosis by tumor necrosis factor-alpha: requirement for TNFR55 and TNFR75 for induction of apoptosis in vitro. , 1997, Blood.

[54]  M. Bevilacqua,et al.  Endothelial-leukocyte adhesion molecules in human disease. , 1994, Annual review of medicine.

[55]  D. Kioussis,et al.  Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. , 1991, The EMBO journal.

[56]  M. Hansen,et al.  Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. , 1989, Journal of immunological methods.

[57]  A. Mantovani,et al.  The recruitment of leukocytes and their interaction with the vessel wall: the role of interleukin-1 and tumor necrosis factor. , 1987, Scandinavian journal of rheumatology. Supplement.

[58]  T. Mosmann.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.